Literature DB >> 25785149

NFKB1 -94ins/del ATTG polymorphism increases osteosarcoma risk in a Chinese Han population.

Xiyi Li1, Chenglin Zhang2, Wei Qiao3, Xuhui Zhou2, Menghong Sun3.   

Abstract

Osteosarcoma is one of the most common bone malignancies. The Nuclear factor-κB1 (NFKB1) gene plays an important role in the pathogenesis of osteosarcoma. The objective of this study aimed to detect the potential association between NFKB1 -94 ins/del ATTG polymorphism and osteosarcoma susceptibility in Chinese Han population. We recruited 220 osteosarcoma patients and 222 cancer-free controls in this case-control study. The NFKB1 -94 ins/del ATTG polymorphism by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Patients with ID genotype and II genotype showed higher risk of osteosarcoma than individuals with DD genotype (OR=1.54, 95% CI 1.00-2.44, P=0.05; OR=1.72, 95% CI 1.01-2.93, P=0.04), respectively. Subjects with ID or II genotype also showed increased risk of osteosarcoma (OR=1.60, 95% CI 1.04-2.47, P=0.03). In addition, I allele was significantly associated with osteosarcoma risk (OR=1.31, 95% CI 1.01-1.71, P=0.04). We also found that this polymorphism was significantly associated with advanced osteosarcoma risk (OR=3.43, 95% CI 1.61-7.36, P=0.001) and metastatic osteosarcoma risk (OR=2.33, 95% CI 1.22-5.03, P=0.01). In conclusion, our findings indicate that osteosarcoma is associated with the NFKB1 promoter -94ins/del ATTG polymorphism.

Entities:  

Keywords:  Nuclear factor-κB; Osteosarcoma; genetics; polymorphism

Year:  2015        PMID: 25785149      PMCID: PMC4358604     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  16 in total

Review 1.  NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions.

Authors:  Jorge Caamaño; Christopher A Hunter
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

2.  Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer.

Authors:  Joanne E Curran; Stephen R Weinstein; Lyn R Griffiths
Journal:  Cancer Lett       Date:  2002-12-15       Impact factor: 8.679

3.  Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk.

Authors:  Meredith S Shiels; Eric A Engels; Jianxin Shi; Maria Teresa Landi; Demetrius Albanes; Nilanjan Chatterjee; Stephen J Chanock; Neil E Caporaso; Anil K Chaturvedi
Journal:  Cancer       Date:  2012-10-08       Impact factor: 6.860

Review 4.  NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases.

Authors:  X-F Sun; H Zhang
Journal:  Histol Histopathol       Date:  2007-12       Impact factor: 2.303

5.  International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

6.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

7.  Single-nucleotide polymorphisms of the PRKCG gene and osteosarcoma susceptibility.

Authors:  Ying Zhang; Xu Hu; Hong-Kai Wang; Wei-Wei Shen; Tong-Quan Liao; Pei Chen; Tong-Wei Chu
Journal:  Tumour Biol       Date:  2014-09-25

8.  GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population.

Authors:  Chaoyin Jiang; Hua Chen; Lei Shao; Yang Dong
Journal:  Med Oncol       Date:  2014-07       Impact factor: 3.064

9.  Rho GTPase-activating protein 35 rs1052667 polymorphism and osteosarcoma risk and prognosis.

Authors:  Jinmin Zhao; Hua Xu; Maolin He; Zhe Wang; Yang Wu
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

10.  Polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients.

Authors:  Zhao Dong-Ju; Xiao Ai-Ju; Tian Yun-Jiao; Zhang Ming-Qiu
Journal:  Pak J Med Sci       Date:  2014-09       Impact factor: 1.088

View more
  4 in total

Review 1.  An updated meta-analysis of 37 case-control studies on the association between NFKB1 -94ins/del ATTG promoter polymorphism and cancer susceptibility.

Authors:  Yi-Qiao Luo; Duan Wang; Teng Gong; Jiang Zhu
Journal:  Oncotarget       Date:  2016-09-06

Review 2.  NFKB1 -94insertion/deletion ATTG polymorphism and cancer risk: Evidence from 50 case-control studies.

Authors:  Wen Fu; Zhen-Jian Zhuo; Yung-Chang Chen; Jinhong Zhu; Zhang Zhao; Wei Jia; Jin-Hua Hu; Kai Fu; Shi-Bo Zhu; Jing He; Guo-Chang Liu
Journal:  Oncotarget       Date:  2017-02-07

3.  Screening of disorders associated with osteosarcoma by integrated network analysis.

Authors:  Yongfeng Dou; Kai Zhu; Zhaozhong Sun; Xiaopeng Geng; Qingmin Fang
Journal:  Biosci Rep       Date:  2019-05-21       Impact factor: 3.840

4.  Genetic association between NFKB1 -94 ins/del ATTG Promoter Polymorphism and cancer risk: a meta-analysis of 42 case-control studies.

Authors:  Duan Wang; Tianhang Xie; Jin Xu; Haoyang Wang; Weinan Zeng; Shuquan Rao; Kai Zhou; Fuxing Pei; Zongke Zhou
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.